Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

US Leads Cushing Syndrome Market Prevalent Cases to 2023 Says a New Report Available at RnRMarketResearch.com
  • USA - English


News provided by

RnR Market Research

Oct 31, 2014, 17:30 ET

Share this article

Share toX

Share this article

Share toX

Cushing Syndrome Market
Cushing Syndrome Market

Dallas, Texas (PRWEB) November 01, 2014 -- Cushing’s syndrome (CS) is a rare disorder caused by prolonged exposure to excess amounts of circulating free glucocorticoids, such as cortisol. Cortisol is a hormone produced by the adrenal glands that has many functions in the body, such as anti-inflammatory action, antiallergic action, antianabolic action, and amino acid catabolic action (Resmini, 2014). CS is associated with increased mortality caused by complications due to excess cortisol (Resmini, 2014). This epidemiological analysis focuses on CS, and four subtypes of CS: Cushing’s disease, ectopic-adrenocorticotropic hormone (ACTH) CS, adrenal adenoma CS, and adrenal carcinoma CS.

Epidemiologists forecast an increase in the diagnosed prevalent cases of CS in the 6MM, from 32,634 diagnosed prevalent cases in 2013 to 34,573 diagnosed prevalent cases in 2023, with an annual growth rate (AGR) of 0.59%. In 2023, the US will have the highest number of diagnosed prevalent cases of CS, with 17,162 diagnosed prevalent cases. Additionally, each of the 6MM will see an increase in diagnosed prevalent cases over the 10-year forecast period, except for Germany, which will have a negative AGR of 0.14%. Because GlobalData epidemiologists applied a constant diagnosed prevalence in each of the 6MM, the trends in the diagnosed prevalent cases of CS are attributed to changing population demographics in the 6MM.

Complete report available @ http://www.rnrmarketresearch.com/epicast-report-cushings-syndrome-epidemiology-forecast-to-2023-market-report.html .

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CS in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). The report also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of CS, Cushing’s disease, ectopic ACTH CS, adrenal adenoma CS, and adrenal carcinoma CS segmented by age (18 to ≥85 years) and sex in these markets. Additionally, GlobalData epidemiologists provide the immediate outcome of transsphenoidal adenomectomy surgery (TSS) in patients with Cushing’s disease.

For this analysis, GlobalData epidemiologists used data available from Orphanet to construct the 10-year epidemiological forecast for the diagnosed prevalent cases of Cushing’s disease, ectopic ACTH CS, adrenal adenoma CS, and adrenal carcinoma CS in the 6MM.

For this analysis, Epidemiologists used data available from Orphanet to construct the 10-year epidemiological forecast for the diagnosed prevalent cases of CS, Cushing’s disease, ectopic ACTH CS, adrenal adenoma CS, and adrenal carcinoma CS in the 6MM. The forecast provides the age- and sex-specific diagnosed prevalent cases of CS subtypes in the six markets, providing a comprehensive view of CS. In addition, this analysis provided detailed, clinically relevant segmentations for Cushing’s disease in order to improve the management of the disease.

Order a Purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=235511 .

Scope

  • The Cushing’s syndrome (CS) EpiCast Report and EpiCast Model provide an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CS in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). The report also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of CS, Cushing’s disease, ectopic- adrenocorticotropic hormone (ACTH) CS, adrenal adenoma CS, and adrenal carcinoma CS segmented by age (18 to =85 years) and sex in these markets.
  • The CS epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.
  • The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=235511 . (This is a premium report priced at US$3995 for a single user License.)

Major Points in Table of Content
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global Trends
3.3.1 US
3.3.2 5EU
3.4 Forecast Methodology
3.4.1 Sources Used
3.4.2 Sources Not Used
3.4.3 Forecast Assumptions and Methods – Prevalent Cases
3.4.4 Forecast Assumptions and Methods – Immediate TSS Outcomes
3.5 Epidemiological Forecast of Cushing’s Syndrome (2013–2023)
3.5.1 Cushing’s Syndrome
3.5.2 Cushing’s Disease
3.5.3 Ectopic ACTH CS
3.5.4 Adrenal Adenoma CS
3.5.5 Adrenal Carcinoma CS
3.5.6 Age-Standardized Diagnosed Prevalence Rates
3.5.7 Immediate TSS Outcomes
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis

Browse more reports on Therapeutics Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Ritesh Tiwari, RnR Market Research, http://www.rnrmarketresearch.com, +1 (888) 391-5441, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.